This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
MarketWatch· Jaimy Lee· Sep 23, 2026 · 12:58 PM
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 8 hours ago
Elon Musk opens the door for a big SpaceX acquisition
The rocket and satellite-internet company is looking to challenge telecom giants.
MarketWatch
marketsabout 8 hours ago
Data centers run on debt. That was a problem for bonds this year — and it’s only going to get worse.
AI debt issuance this year overwhelmed investor portfolios, and has disappointed from a performance perspective. The funding need won’t get any better with Democrats in control of Congress.
MarketWatch
marketsabout 9 hours ago
Micron’s stock is dirt cheap — and that’s igniting a fierce online debate
Valuation purists see a ridiculously inexpensive stock, but some semiconductor investors say Micron’s earnings power won’t hold up.
MarketWatch